Conference abstract · 1 Dec 2018
Conference abstractPublished 6 Aug 2018
Pharmacogenomics merges with immunotherapy as world leader in cancer therapy
American International Medical University, St. Lucia
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
The most common cancer in women is breast cancer which is observed in both developed and less developed world. In the report published earlier for statistics of breast cancer, the number of new diagnosed cases accounted for 882,900 whereas death counted because of this disease was 324,300. The original belief is that breast cancer is a disease associated with women from developed world, however the recent data contradicts the concept indicating 50% of new breast cancer cases and 58% of deaths because of breast cancer is reported from less developed countries. Traditional method of assessment of risk of breast cancer in women is measured by considering family history, pre-existing conditions, and previous treatments. It also include reproductive and endocrine factors such as the use of oral contraceptives, never having children, and a long menstrual history. There is significant evidence suggesting that hormone replacement therapy for post-menopausal women increases risk for breast cancer, both ductal and lobular breast cancer. Life style factors including drinking, obesity, physical inactivity, and use of menopausal hormone therapy have considerable association in risk of developing breast cancer. Advanced studies in breasted has classified this disease into four subtypes: Luminal A (ER+/PR+/HER2âÂ?Â?, grade 1 or grade 2), Luminal B (ER+/PR+/HER2+, or ER+/PR+/HER2âÂ?Â? grade 3), HER2 overexpression (ERâÂ?Â?/PRâÂ?Â?/HER2+), and triple negative breast cancer (TNBC, ERâÂ?Â?/PRâÂ?Â?/ HER2âÂ?Â?). Luminal A subtype has a good prognosis with least resistance to endocrine therapy hence the endocrine therapy model is alone used for patients under this subtype. Cancers with high rate of tumor proliferation with HER2 negative are classified under subtype Luminal B, and the treatment includes therapy + chemotherapy. On the other hand cancers with HER2-positive Luminal B subtype are normally treated with chemotherapy + anti-HER2 treatment + endocrine therapy. Chemotherapy + anti-HER2 treatment is the principal recommended treatment for HER2 overexpression subtype with poor prognosis and rapid progression. The negative expression of ER, PR and HER2 in TNBC has unique biological characteristics and strong heterogeneity, no standard treatment but chemotherapy is suggested for the subtype. In the decision making for treatment of breast cancer, clinical and histopathologic characteristics play critical roles since many years. The role of pharmacogenetics in the personalization of breast cancer therapy has relevance in the management of breast cancer.
Subjects
Immunology & MicrobiologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract · 1 Dec 2018
Immunology World 2018 - Pharmacogenomics merges with immunotherapy as world leader in cancer therapy, Satyajit Patra, American International Medical University, Saint Lucia
Perspective · 18 Sep 2024
Managing Life with Cancer: Merging Inheriting and Palliative Therapy in Contemporary Oncology
Perspective · 27 Dec 2024
Customising Cancer Immunotherapy: Adapting Therapy to the Patient and the Tumor
Perspective · 30 Nov 2024
The Future of Immune Checkpoint Inhibitors in Cancer Treatment: Combining Immunotherapy with Targeted Therapies
More from this journal
The newest in Journal of Clinical and Cellular Immunology.
Perspective · 10 Sep 2026
Cellular Pathways Involved in Mucosal Immunity and Protection Against Environmental Challenges
Commentary · 22 Jul 2026
From Bench to Bedside: Reframing the CXCL13/CXCR5 Axis as a Non-Redundant Organizer of Protective Pulmonary Immunity in COVID-19
Commentary · 17 Jul 2026
CD5L:p40, a third wheel to IL-12 and IL-23 biology?
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Clinical and Cellular Immunology
- SubjectImmunology & Microbiology
- BylineArticles whose byline prints “Satyajit Patra”

